Werewolf Therapeutics (HOWL) Earnings
Price: $0.89
Market Cap: $39.93M
Market Cap: $39.93M
Revenue (TTM): $1.89M
Net Income: $-70.52M
Net Income: $-70.52M
P/E Ratio: -0.56
EPS (TTM): $-1.59
EPS (TTM): $-1.59
Earnings Dates
Werewolf Therapeutics (HOWL) reports its earnings quarterly. Here are the key details:
Next Earnings Date
- Date: May 02, 2025
- Time of Day: Before Market Open
- Estimated EPS: $-0.44
Last Earnings Report
- Date: March 11, 2025
- EPS: $-0.46
- EPS Estimate: $-0.43
Werewolf Therapeutics's next earnings report is scheduled for May 02, 2025.
In its last earnings report on March 11, 2025, Werewolf Therapeutics reported earnings per share (EPS) of $-0.46, compared to an estimated EPS of $-0.43. The company reported revenue of $-, compared to an estimated revenue of $301.59K.
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Earnings History
| Date | EPS | EPS Estimate | Revenue | Revenue Estimate |
|---|---|---|---|---|
| March 11, 2025 | $-0.46 | $-0.43 | $- | $301.59K |
| November 07, 2024 | $-0.38 | $-0.41 | $- | $709.32K |
| August 08, 2024 | $-0.43 | $-0.38 | $1.14M | $841.78K |
| May 03, 2024 | $-0.39 | $-0.35 | $742.00K | $1.46M |
| March 07, 2024 | $-0.33 | $-0.43 | $1.50M | $1.94M |
| November 14, 2023 | $-0.23 | $-0.27 | $5.90M | $1.59M |
| August 10, 2023 | $-0.14 | $-0.41 | $8.08M | $3.15M |
| May 11, 2023 | $-0.34 | $-0.49 | $4.46M | $2.03M |
| March 23, 2023 | $-0.39 | $-0.59 | $7.28M | $2.07M |
| November 10, 2022 | $-0.40 | $-0.60 | $4.97M | $3.05M |
| August 11, 2022 | $-0.53 | $-0.30 | $4.15M | $5.00M |
| May 10, 2022 | $-0.56 | $-0.60 | $- | $- |
| March 24, 2022 | $-0.66 | $-0.56 | $- | $- |
| November 10, 2021 | $-0.51 | $-0.45 | $- | $- |
| August 12, 2021 | $-3.82 | $-0.28 | $- | $- |
| June 10, 2021 | $-83.36 | $-0.46 | $- | $- |
| April 30, 2021 | $-0.83 | $ | $- | $- |
| September 29, 2020 | $-0.68 | $ | $- | $- |
| June 29, 2020 | $0.25 | $ | $- | $- |
Annual Earnings
Annual Revenue
$1.89M
Fiscal Year 2024Annual Net Income
$-70.52M
Fiscal Year 2024Annual EPS
$-1.63
Fiscal Year 2024Quarterly Earnings
Revenue
$-
Quarter Ending December 31, 2024Net Income
$-20.40M
Quarter Ending December 31, 2024EPS
$-0.46
Quarter Ending December 31, 2024Earnings Metrics
Earnings Yield
-109.95%
Year Ending December 31, 2024P/E Ratio
-0.91
Year Ending December 31, 2024Revenue Per Share
$0.04
Year Ending December 31, 2024Earnings Yield (TTM)
-177.99%
Trailing Twelve MonthsP/E Ratio (TTM)
-0.56
Trailing Twelve MonthsRevenue Per Share (TTM)
$0.04
Trailing Twelve MonthsFrequently Asked Questions
Werewolf Therapeutics's next earnings date is scheduled for May 02, 2025. The earnings call is expected to take place before market open.
In its last earnings report on March 11, 2025, Werewolf Therapeutics reported earnings per share (EPS) of $-0.46, compared to an estimated EPS of $-0.43. The company reported revenue of $-, compared to an estimated revenue of $301.59K.
Werewolf Therapeutics's current Price-to-Earnings (P/E) ratio is -0.91. The trailing twelve months (TTM) P/E ratio is -0.56. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.
For the fiscal year ending December 31, 2024, Werewolf Therapeutics reported total revenue of $1.89M and net income of $-70.52M. This represents a net profit margin of -37.4084880637.
Werewolf Therapeutics's earnings yield is -109.95%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.
Werewolf Therapeutics's return on equity (ROE) is -96.08%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.
Werewolf Therapeutics's gross profit margin is 100.00%. This indicates that for every dollar of revenue, the company retains $1.00 as gross profit after accounting for the cost of goods sold.